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Abstract
Background: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of osteoporotic fracture. Several
factors have been identified as being potentially responsible for this risk, such as alterations in bone remodelling
that may have been induced by changes in circulating glucose or/and by the presence of non-oxidative end
products of glycosylation (AGEs). The aim of this study is to assess whether such variations generate a change in
the gene expression related to the differentiation and osteoblast activity (OPG, RANKL, RUNX2, OSTERIX, and AGE
receptor) in primary cultures of human osteoblast-like cells (hOB).
Methods: We recruited 32 patients; 10 patients had osteoporotic hip fractures (OP group), 12 patients had osteoporotic
hip fractures with T2DM (T2DM group), and 10 patients had hip osteoarthritis (OA group) with no osteoporotic fractures
and no T2DM. The gene expression was analyzed in hOB cultures treated with physiological glucose concentration
(4.5 mM) as control, high glucose (25 mM), and high glucose plus AGEs (2 μg/ml) for 24 h.
Results: The hOB cultures from patients with hip fractures presented slower proliferation. Additionally, the hOB
cultures from the T2DM group were the most negatively affected with respect to RUNX2 and OSX gene expression
when treated solely with high glucose or with high glucose plus AGEs. Moreover, high levels of glucose induced a
major decrease in the RANKL/OPG ratio when comparing the OP and the T2DM groups to the OA group.
Conclusions: Our data indicates an altered bone remodelling rate in the T2DM group, which may, at least partially,
explain the reduced bone strength and increased incidence of non-traumatic fractures in diabetic patients.
Abbreviations: AGER, Advanced glycation end products receptor; AGEs, Advanced glycation end products;
AP, Alkaline phosphatase; BMD, Bone mass density; BMI, Body mass index; cDNA, Complementary deoxyribonucleic
acid; DM, Diabetes mellitus; DMEM, Dulbecco’s modified eagle medium; HbA1c, Glycated haemoglobin; hOB, Human
osteoblasts-like cells; IGF-I, Insulin-like growth factor I; OA, Osteoarthritis; OP, Osteoporosis; OPG, Osteoprotegerin;
OSX, Osterix; P1NP, Procollagen I N-terminal peptide; PBS, Phosphate-buffered saline; PSF, Penicillin/streptomycin/
fungizone mix; PTH, Parathyroid hormone; RANK, Receptor activator of nuclear factor kβ; RANKL, Receptor activator of
nuclear factor kβ ligand; RNA, Ribonucleic acid; T2DM, Type 2 diabetes mellitus; β-CTX, Carboxy-terminal telopeptide of
type I collagen
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Background
Type 2 diabetes mellitus (T2DM) and osteoporosis (OP) are
two diseases with a high prevalence in developed countries.
Both of these diseases are associated with a high morbidity
and mortality rate and an increased risk of frailty fractures
[1]. Hip fracture is the most devastating frailty fracture due
to its associated high mortality and the low number of pa-
tients that recover functional activity and independence [2].
Various studies indicate an increased risk of fracture in
T2DM. This risk varies depending on the type of study
and the fracture location assessed. The incidence of frailty
hip fractures in these patients is up to 2.8 times greater
than in the general population [2]. Diabetes-related com-
plications (retinopathy, neuropathy, kidney diseases, or
vascular damages) may alter skeletal bone remodelling,
since they impose a direct effect on bone strength and/or
the probability of falls, thus increase the risk of fractures.
Other aspects of diabetes, such as high levels of AGEs in
bone collagen and/or hyperglycaemia in bone micro-
environments, have also been considered as triggers to in-
creased bone fragility [3]. Although many factors have
been proposed, very few studies have analyzed the import-
ance of each factor and the intimate mechanism of action
on the deterioration of bone metabolism.
In bone formation, the signals that determine the differ-
entiation, survival, and replication of osteoblastic cells are
critical for suitable bone metabolism. Those signals that
may be essential include: those involved in osteoblastic
proliferation and differentiation, such as RUNX2 and
OSTERIX (OSX); the signals involved in the osteoblast-
osteoclast coupling process for bone remodelling, such as
osteoprotegerin (OPG) and the receptor activator of nu-
clear factor-kβ ligand (RANKL); and the signals related to
other common diabetic disease complications, such as
AGE receptor (AGER). These signals may be affected in
diseases, such as T2DM, due, at least in part, to common
metabolic conditions in diabetic patients, such as high
levels of glucose and/or AGEs. In this regard, there have
been previous studies in animal models, in cell lines, and
in primary human osteoblast (hOB) cultures [4−10] but,
to the best of our knowledge, no previous studies have
been carried out in hOB cultures from cancellous bone
biopsies of diabetic patients.
The aim of this study is to assess the influence of T2DM
on bone metabolism. For this purpose, primary human
osteoblast-like cells were stimulated by using solely a high
glucose concentration, and by using a high glucose concen-
tration plus advanced glycation end products (AGEs), which
are similar to the conditions found in diabetic patients.
Methods
Study design and subjects
The Ethics Committee of the Virgen Macarena Hospital
approved this cross-sectional study, and informed written
consent was obtained from all participants. All patients in-
cluded in the study agreed to donate their bone samples.
The studied population consisted of three groups of pa-
tients. The first group consisted of 12 patients (1 man/11
women; 85 ± 9 years old) with osteoporotic fractures and
T2DM (T2DM). The second group consisted of 10 pa-
tients (5 men/5 women; 81 ± 6 years old) with osteopor-
otic fractures (OP) without DM. The last group consisted
of 10 patients (3 men/7 women; 68 ± 11 years old) with
osteoarthritis (OA) without DM. The osteoarthritic sam-
ples (OA) were considered the reference group because
the bone mineral density (BMD) values classified them as
non-osteoporotic. The inclusion criterion for all of the
groups was that patients must be aged over 50. The inclu-
sion criteria for T2DM patients were the following: a) di-
agnosed with DM for more than 5 years; and b) a current
frailty hip fracture (a fall from less than the patient’s height
without an acceleration mechanism). For the OP group,
patients had to have a frailty hip fracture without diabetic
syndrome. Finally, OA patients could not have been previ-
ously diagnosed with osteoporosis or diabetes nor could
they have a history of frailty fracture since the age of 50.
The exclusion criteria for all of the groups included
malignant diseases, hyperthyroidism, hyperparathyroid-
ism, osteomalacia, previous bisphosphonate or systemic
steroid treatment, and current use of hormone replace-
ment therapy or any other drugs with negative effects on
bone metabolism. All T2DM patients were being treated
for diabetes, primarily with metformin, and only two pa-
tients were being treated with insulin.
Patients were included in the study in a consecutive
manner (February 2013 to February 2014). Arthroplasty
was performed in the Orthopaedics & Traumatology De-
partment of the Virgen Macarena University Hospital
(Seville, Spain) for all groups.
Standardized interviews and self-reported questionnaires
were used to obtain the following information: age (years),
weight (kg), height (cm), body mass index (BMI) (kg/m2),
use of calcium and vitamin D supplements (none vs. any),
use of medication, and family history of hip fracture.
Bone mineral density (BMD)
Total hip and femoral neck BMD was measured at the
contralateral hip using a dual X-ray densitometer (Holo-
gic-Discovery, Hologic Inc.). The in vivo CV was 1 %
(total BMD).
Biochemical serum measurements
Fasting morning blood was drawn and stored at −80 °C.
We assessed glucose, glycated haemoglobin (HbA1c), cre-
atinine, cholesterol, triglycerides, calcium, phosphorus,
and total alkaline phosphatase (AP) using an autoanaly-
zer (ADVIA 2400, Siemens; inter-assay CVs were 1.4, 1,
3.7, 1.2, 2, 3.7, 1.5, 1.5, and 3 %, respectively). Insulin-
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like growth factor I (IGF-I) was determined using a
chemiluminescence immunoassay (CLIA) by autoanaly-
zer (IMMULITE 2000, Siemens; inter-assay CV was
6.9 %). Vitamin D [25(OH)D3] and the parathyroid hor-
mone (PTH) were determined by CLIA using an immuno-
assay analyser (CP ADVIA Centaur, Siemens; inter-assay
CVs were 20 and 4.3 %, respectively). Carboxy-terminal
telopeptide of type I collagen (β-CTX) and procollagen I
N-terminal peptide (P1NP) were analyzed by an electro-
chemiluminescence immunoassay (ECLIA) using an
autoanalyzer (ADVIA 2400, Siemens; inter-assay CVs
were 2.9, 3.3 %, respectively). In all cases, the intra-
assay CV was < 5 %.
Cell culture and treatment with glucose and AGEs
During the total hip replacement, the femoral head
was removed. Cancellous bone was cut into small
pieces (1–2 mm) and placed in culture dishes. Bone pieces
were gently washed several times with phosphate-buffered
saline (PBS; Lonza) and nourished with Dulbecco’s modi-
fied eagle medium (DMEM) of 4.5 mM glucose containing
20 % heat-inactivated foetal bovine serum (FBS; Lonza)
and 1 % Penicillin/Streptomycin/Fungizone (PSF) (Penicil-
lin 100 U/mL and Streptomycin 100 mg/L (Sigma); Fungi-
zone 250 μg/mL), and kept at 37 °C in a humidified
atmosphere of 95 % air and 5 % CO2. After 7 days, the
cells began to migrate from bone pieces and the culture
medium was replaced every 2 to 3 days, at 80 % conflu-
ence of cells. The cells were then passaged with a trypsin-
EDTA solution (Sigma) and plated in 6-well dishes at a
density of 0.3×106 cells/well for subsequent experiments.
At 80 % sub-confluence, hOBs were growth-arrested for
24 h in serum-free DMEM containing 1 % PSF, and were
then stimulated. To determine the effects of high glucose,
either alone or together with AGE conditions on osteo-
blastic cells, cultures were cultivated in DMEM containing
physiological glucose level (4.5 mM) or containing high
levels of glucose concentration (25.5 mM), or high glu-
cose plus AGEs (25 mM glucose and AGEs of 2 μg/ml)
for 24 h. Osteoblast-like cell cultures were obtained
from OA patients (n = 10), OP patients (n = 10), and
T2DM patients (n = 12). The number of cells (index of
proliferation) was counted with a haemocytometer. The
trypan blue stain was used to screen dead cells after
harvesting. Characterization of the osteoblastic pheno-
type was performed by measuring the alkaline phos-
phatase activity as previously described [11], with
staining in all cultures. More than 85 % of the cells
were positive for alkaline phosphatase.
Physiological glucose dosage (4.5 mM) was used as a
control condition. High glucose and AGE dosages and
time of exposure were chosen based on previous studies
[5, 9, 12]. These concentrations are similar to those
found in decompensated diabetic patients.
Real-time PCR
Total RNA was isolated using the High Pure RNA Isola-
tion Kit (Roche), according to the manufacturer's instruc-
tions. RNA concentration and purity were determined by
A260 and A280 (A260/A280 = 1.7–2.0) measurements
using a GeneQuant spectrophotometer (Amersham Bio-
sciences. Cambridge, U.K.). Reverse transcription of total
RNA (1 μg) was performed with the QuantiTec Reverse
Transcription Kit (Qiagen) in accordance with the
manufacturer’s instructions. The cDNAs were used for
qRT-PCR analysis and all probes were analyzed for
genes of interest (in duplicate): RUNX2, OSX, OPG,
RANKL, and AGER. The QuantiTect Primer Assays
were purchased from Qiagen: QT00020517 (RUNX2),
QT00213514 (OSX), QT00014294 (OPG), QT00215614
(RANKL), QT00996625 (AGER), and QT00199367 (18S
ribosomal). The cDNAs were amplified with SYBR Green
PCR Master Mix (Sigma-Aldrich) in a StepOnePlus™ Real-
Time PCR System (Applied Biosystems). The data was nor-
malized to 18S ribosomal gene expression to obtain ΔCt.
The 2−ΔΔCt method was employed to calculate the gene
expression differences between groups and the stimulated
vs. physiological glucose. The results are expressed as
arbitrary unit ± SEM.
Statistical analysis
The results were analyzed using the SPSS 22.0 statistical
software. Comparison of anthropometric data was per-
formed using the two-way ANOVA test. Gene expres-
sion analysis was performed using the univariate general
linear model (full factorial model) for inter-group com-
parisons, and an analysis of a general linear model with
repeated measures (full factorial model) was used for
intra-group comparisons. An adjustment for age was ap-
plied when needed. Correlation between variables was
carried out by Pearson and Spearman’s Rho coefficient.
The results with a p < 0.05 were considered statistically
significant.
Results
T2DM patients were older (85 ± 9 years) than OP (81 ±
6 years) and OA (68 ± 11 years) patients (Table 1). Due to
these differences, an adjustment for age was applied to the
successive statistical analyses. No differences were found in
weight, height, or BMI between the study groups (Table 1).
Total hip and femoral neck BMD in both fractured
groups, OP and T2DM, were fewer than the OA group.
The T2DM group presented the lowest BMD values;
however, after adjusting for age, these results were not
significantly different (Table 1).
The biochemical profile of the three groups of patients
(Table 2) was very similar, and we only observed differ-
ences in HbA1c (T2DM: 6.12 ± 0.77 % vs. OP: 5.20 ±
0.28 %, p = 0.011; T2DM vs. OA: 5.18 ± 0.29 %, p = 0.002).
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We also found major differences in the vitamin D
levels. All of the groups showed mean vitamin D values
lower than 20 ng/ml, but the OP group had the lowest
values (OP: 7.62 ± 3.09 ng/ml vs. OA: 17.58 ± 11.45 ng/
ml, p = 0.01). The bone turnover markers assessed were
P1NP, β-CTX, and AP. We found greater mean β-CTX
values in the two fracture groups compared with the con-
trol group, especially in the OP group (OP: 0.72 ± 0.22 ng/
ml vs. OA: 0.36 ± 0.20 ng/ml, p = 0.022). There were no
differences in P1NP serum levels among the groups, nor
were there differences in AP levels.
The proliferation of hOB in cultures from the T2DM
patients was the slowest, and all of the cultures demon-
strated different times for their confluence (32 ± 10 days
for T2DM; 30 ± 11 days for OP; 21 ± 4 days for OA).
Gene expression
The expression of genes encoding RUNX2, OSX, AGER,
OPG, and RANKL were compared between those of the
fractured groups (OP and T2DM) and of the OA group
and referred to physiological glucose (Figs. 1 and 2). The
results were reported in relative units of expression
(r.u.). An adjustment for age was implemented in the
statistical analyses.
RUNX2 expression levels (Fig. 1a) were constant in all
of the culture conditions for the OA and OP groups, al-
though the OP group consistently demonstrated lower
levels (by approximately 50 %) than the OA group. In
the T2DM group, the RUNX2 expression was similar to
that of OA, but was lower (by approximately 50 %) in
conditions of high glucose concentration. In the diabetic
group, the expression of RUNX2 in conditions of high
glucose was significantly lower than this expression in
high glucose plus AGEs (HGlu: 0.550 ± 0.160 r.u.,
HGlu + AGEs: 0.872 ± 0.224 r.u.; p = 0.042).
The OSX gene expression (Fig. 1b) was markedly
lower in both groups of patients with hip fracture than
in the control group, and the OP group had the lowest
values for all conditions. High glucose and high glucose
plus AGEs reduced the OSX gene expressions in the two








HbA1c (%) 5.18 ± 0.29 5.20 ± 0.28 6.12 ± 0.77 **0.002
***0.011
Glucose (mg/dl) 88.30 ± 29.4 109.17 ± 34.1 117.40 ± 37.8 –
Cholesterol (mg/dl) 168.33 ± 44.0 115.33 ± 28.3 148 ± 25.4 *0.029
Triglycerides (mg/dl) 110.44 ± 44.0 107.33 ± 31.5 130.3 ± 37.2 –
Creatinine (mg/dl) 1.06 ± 0.56 1.17 ± 0.41 0.86 ± 0.17 –
Calcium (mg/dl) 9.47 ± 0.51 9.27 ± 0.43 9.37 ± 0.44 –
Phosphorus (mg/dl) 3.18 ± 0.53 2.98 ± 1.01 2.94 ± 0.54 –
IGF-1 (ng/ml) 67 ± 35.15 45.33 ± 26.57 43.5 ± 18.35 –
Vitamin D (ng/ml) 17.58 ± 11.45 7.62 ± 3.09 12.38 ± 7.72 *0.01
PTH (pg/ml) 42.94 ± 20.61 70.33 ± 43.64 64.90 ± 49.74 –
P1NP (ng/ml) 48.38 ± 25.10 54.49 ± 16.23 54.78 ± 38.61 –
β-CTX (ng/ml) 0.36 ± 0.20 0.72 ± 0.22 0.54 ± 0.30 *0.022
AP (UI/l) 172.2 ± 73.79 211.17 ± 36.47 192.9 ± 80.50 –
*OA vs. OP; **OA vs. T2DM; ***OP vs. T2DM








Age (years) 68 ± 11 81 ± 6 85 ± 9 *0.009
**0.001
BMI (Kg/m2) 33.27 ± 5,15 27,91 ± 5,93 29,73 ± 5,74 –
Femoral neck BMD (gHA/cm2) 0.72 ± 0.19 0.52 ± 0.11 0.47 ± 0.03 –
Total hip BMD (gHA/cm2) 0.89 ± 0.14 0.77 ± 0.169 0.62 ± 0.103 –
Femoral neck T-score −1.39 ± 1.41 −3.10 ± 0.87 −3.40 ± 0.26 –
Total hip T-score −0.76 ± 0.79 −1.68 ± 1.07 −2.63 ± 0.83 –
*OA vs. OP; **OA vs. T2DM
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groups of patients with fractures: OP and T2DM. The
mRNA levels were significantly lower in the case of the
OP group compared with those of the OA group for the
two treatments (OP vs. OA. HGlu, p = 0.033; HGlu +
AGEs, p = 0.015).
At low glucose, AGER expression values (Fig. 1c) were
slightly lower in the two pathologic groups than in the
control group. This difference was accentuated when the
cultures were subjected to a high glucose medium, with
lower expression (28.11 %) in the diabetic group. In the
case of the high glucose medium plus AGEs, the OP
group showed no change from the baseline or from the
high glucose condition. However, the T2DM group pre-
sented a higher AGER expression compared with the
values observed in the low and high glucose experimen-
tal conditions (34 and 52.56 %, respectively).
The OPG gene expression (Fig. 2a) was greater in the
OP and T2DM groups compared with those in the OA
group for all the experimental conditions. We found no
difference between the groups in a high glucose condition.
Fig. 1 Gene expression of RUNX2 a OSX b and AGER c Osteoblasts
from OA patients (n = 10), OP patients (n = 10) and T2DM patients
(n = 12) were treated with low glucose as control (4.5 mM; Glu), high
glucose (25 mM; HGlu) and high glucose + AGEs (2 μg/ml; HGlu + AGEs)
during 24 h. The results were normalized to 18S ribosomal and adjusted
for age in the statistical analyses. The data is expressed as mean ± SEM
(relative units). (*statistically significant at p < 0.05)
Fig. 2 Gene expression of OPG a and RANKL b and the RANKL/OPG
ratio c Osteoblasts from OA patients (n = 10), OP patients (n = 10)
and T2DM patients (n = 12) were treated with low glucose as control
(4.5 mM; Glu), high glucose (25 mM; HGlu) and high glucose + AGEs
(2 μg/ml; HGlu + AGEs). The results were normalized to 18S ribosomal
and adjusted for age in the statistical analyses. The data is expressed as
mean ± SEM (relative units). (*statistically significant at p < 0.05)
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In contrast, the high glucose medium plus AGEs in-
creased the OPG expression levels in the two fractured
groups with an increase of 35.71 and 50.27 % with respect
to low glucose, and an increase of 57.62 and 52.02 % with
respect to high glucose (OP and T2DM, respectively). The
difference in expression when the AGEs were added to
the high glucose medium was significantly greater in the
OP group than in the OA group (OP vs. OA, p = 0.041)
and was also significantly greater in the T2DM group
when subjected to high glucose (HGlu. vs. HGlu + AGEs,
p = 0.046).
The RANKL levels of expression (Fig. 2b) in low glucose
were similar in all groups and remained stable under all
culture conditions in the OA group. A significant reduc-
tion of the RANKL expression was observed in a high
glucose medium for the two fractured groups compared
with the OA group (OA vs. OP, p = 0.012; OA vs. T2DM,
p = 0.002). In a high glucose medium plus AGEs, the two
fractured groups showed similar expression values as
those in the OA group. However, the diabetic group had a
significantly greater expression (69.46 %) than the ex-
pression observed in high glucose conditions (HGlu vs.
HGlu + AGEs, p = 0.015).
The RANKL/OPG ratio values (Fig. 2c) in the two
fractured groups were lower than in the OA group for
all culture conditions. In the case of high glucose, the ra-
tio in the two fractured groups fell by 63.18 and 82.53 %
(OP and T2DM, respectively) with respect to low glu-
cose, with the two measures being significantly less
than those in the OA group. Finally, the RANKL/OPG
ratio of the OP group in a high glucose medium plus
AGEs was significantly less than in low glucose (Glu vs.
HGlu + AGEs, p = 0.02).
Mannitol, which was used as an osmolarity control,
had no effect on the hOB cells (data not shown). Gene
expression failed to correlate with age, BMI, or the bio-
chemical parameters analyzed.
Discussion
It is well accepted that diabetes mellitus (DM) increases
the risk of fragility fractures. The mechanisms by which
such impairments occur remain unclear, but long-term
exposure to high glucose levels in patients with T2DM
may lead to decreased bone remodelling which, in turn,
may lead to structural deterioration. This could explain
the well-documented higher risk for fracture despite
preservation or an increase in BMD in patients with type
2 diabetes [1–3, 13, 14]. We have studied whether high
glucose alone or, with the addition of AGEs in the pri-
mary culture of osteoblast-like cells (hOB) from diabetic
patients, is able to promote changes in the proliferation,
differentiation and/or function of these cells as a pos-
sible explanation for bone fragility in T2DM patients.
For comparison purposes, we analyzed the effect of these
treatments on cultures of hOB from patients with osteo-
arthritis as a control group [11].
The hOB cultures from the patients with hip fractures
had slower proliferation rates than those from the OA
group, and those from T2DM patients had the slowest
proliferation rates. Due to the age difference between
the groups, proliferation was not statistically different.
These results are consistent with the idea that osteo-
blasts from OP patients are characterized by a slower
growth [11] and that high glucose reduces osteoblast
viability and proliferation [15–17].
The differentiation of osteoblasts is regulated by a net-
work of interacting transcription factors, with Runx2 as the
key player. In osteoblasts, this factor acts by binding to
OSE2, in the promoter region of many genes crucial for
osteoclast regulation, such as osteoprotegerin (OPG) and
the receptor activator of nuclear factor-kβ ligand (RANKL).
Runx2, and its target genes, also constitute crucial compo-
nents of the organic matrix formation, such as osteocalcin,
osteopontin and collagen type I alpha 1. Similarly, Osterix
(OSX) is also an essential transcriptional factor for the
differentiation of osteoblasts and matrix mineralization.
Osx acts downstream of Runx2, and requires its signalling
in order to be expressed. Osx drives osteoblasts to the late
stage of maturation, and inhibits its proliferation by re-
gulating the Wnt/β-catenin canonical pathway [18].
It is well known that Runx2 and Osx are key osteogenic
transcription factors that are required for osteoblastic dif-
ferentiation from mesenchymal stem cells (MSCs) [6].
Our results showed that hOB from T2DM patients were
negatively affected with respect to RUNX2 and OSX gene
expression when subjected to high glucose alone or to-
gether with AGEs in the culture medium, which is con-
sistent with the data reported by other authors [4–8].
Recently, a down-regulation in RUNX2 and OSX expres-
sion has been demonstrated in pre-osteoblastic SCP-1
cells treated with serum from T2DM patients [19]. How-
ever, an increase in the expression of these genes [9, 18]
or no variation in the expression [20] have also been re-
ported by other authors. These apparently contradict-
ory effects of high glucose in the various studies on the
osteoblastic differentiation process may be due to the
heterogeneity of the cell sources and to differences in
the experimental procedures tested. A down-regulation
or lack of RUNX2 and/or OSX is generally associated
with a lower proliferation and differentiation of osteo-
blastic cells [21, 22].
OPG/RANK/RANKL is the most important intercom-
munication system between osteoblasts and osteoclasts,
and many of the systemic drugs, cytokines, and growth
factors influencing bone remodelling act on bone
through this system. Acting as a decoy receptor, OPG
blocks RANKL action and thereby balances bone turn-
over [23, 24]. The expression of OPG in basal glucose
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was greater in the hOB cultures from both fractured
groups, OP and T2DM, whereas RANKL expression was
similar in all 3 groups. However, high levels of glucose
induced a major decrease in the expression of RANKL
in the OP group and even more in the T2DM group, but
OPG expression was not modified in any groups. These
results indicate that high glucose suppresses bone re-
sorption by decreasing RANKL expression, a decrease
that seemed to be alleviated by the overstimulation of
AGER when AGEs were added, as noticed by other au-
thors [25]. In this regard, previous studies performed in
osteoblastic and osteocyte cell lines [26] and in diabetic
animals have demonstrated inconsistent results, showing
both an increase and a decrease in the expression of
OPG and RANKL [7, 9, 27] or no variation whatsoever
[6]. The treatment with a high glucose medium plus
AGEs produced a significant increase in OPG expression
in the hOB cultures from the OP and T2DM groups.
High OPG levels have been linked with macrovascular
and microvascular damage in DM patients [28, 29]. Fur-
thermore, a strong increase in OPG expression might
cause a decrease in the bone remodelling cycle and con-
tribute towards the vascular calcification that is so often
found in diabetic patients [30].
When the RANKL/OPG ratio was analyzed, which is a
potential osteoclastic marker, we observed that both treat-
ments (HGlu and HGlu + AGEs) produced a notable re-
duction in both the OP and T2DM groups. Previous
studies have pointed out that there is an imbalance in the
RANKL/OPG ratio in the diabetic disease [6, 7, 9, 27]. To
the best of our knowledge, no previous studies have been
performed in hOB cultures from diabetic patients, al-
though high OPG and low RANKL serum levels have
been reported in patients with type 1 and type 2 diabetes
[28, 29]. In this study, we simulated the metabolic condi-
tions of poorly controlled T2DM patients, such as hyper-
glycaemia and high AGEs, in the hOB cultures.
Finding a decreased RANKL/OPG ratio implies a sup-
pressed bone turnover process. Over the years, this dele-
terious effect on bone and the diminished ability for
bone formation represent the origin of the greater frailty
of diabetic bone.
In prolonged hyperglycaemia found in advanced and
poorly controlled diabetes mellitus, glucose reacts with
proteins to form advanced glycation end products (AGEs)
[10]. The coupling of AGEs with the receptor (AGER) on
osteoblastic lineage cells results in a reduction of the
antioxidant mechanisms and increased synthesis of free-
oxygen radicals, which coincides with the increased ex-
pression of RANKL and promotes the differentiation and
activation of the osteoclasts and bone resorption [25] and
induces the osteoblast apoptosis [31]. Additionally, ele-
vated levels of AGEs alter the mineralization and repair of
microdamage in bone tissue through the formation of
crosslinks in collagen, which alters the bone mechanics
[32, 33]. The natural accumulation of AGEs with age in-
creases in diabetes and chronic inflammatory diseases,
which points to AGEs as an essential factor in the impair-
ment of bone quality in T2DM.
When we analyzed AGER expression levels, no sig-
nificant changes were found. However, AGEs, in
addition to high glucose, induced a slight increase in
AGER expression, as observed by other authors [34].
This increased expression may contribute towards de-
creased bone formation since increased AGER produces
an inhibition of osteoblast proliferation by depressing
Wnt signalling via PI3K and ERK and by suppressing
OSX expression [10, 35]. It is expected that poorly con-
trolled diabetes patients have high circulating levels of
AGEs for prolonged periods throughout their lifetime,
which induces a more striking increase in AGER expres-
sion than found in our experiment. Our patients practised
very good metabolic control of their diabetes and were
primarily treated with metformin. This anti-diabetic drug
has been reported to be able to reduce the AGER protein
levels in osteoblast-like cell lines [17, 36]. Therefore, an-
other reason for the low AGER mRNA values in the hOB
cultures from diabetic patients could be due to a residual
effect of bone adaptation to metformin in these patients,
because eight of these patients were taking this drug for at
least 1 year prior to hip fracture. Nevertheless, the role of
the AGE receptor in bone fragility in diabetic patients has
yet to be fully ascertained.
The study had several limitations. Regarding gene expres-
sion of osteoblast-like cell cultures, the results presented a
large intra-group variability. This may be the reason why
some of the observed intra- or inter-group differences
showed certain tendencies but did not attain statistical
significance. Another limitation was that we focussed on
gene expression of the cells and the mineralization capacity
was not assessed. It is possible that high glucose and/or
AGE levels may also have an effect on the differentiation
and function of osteoclasts, but this has not been assessed
in this study. Future studies should examine the effects of
high glucose and/or AGEs on these cells solely and/or co-
cultured with osteoblasts. Another limitation of the study
was the good metabolic control of diabetes found in our
T2DM patients, as demonstrated by the HbA1c and trigly-
ceride serum levels and by the fact that there were no
additional complications. Despite these drawbacks, a strong
point of this study is the use of primary cultures of human
osteoblasts, which are an excellent model and are better
than cell lines or animals for the evaluation of human bone
pathologies.
Conclusions
Our study provides the first experimental evidence of
the deleterious effect of high levels of glucose and AGEs
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in RUNX2 and OSX expression. Moreover, T2DM osteo-
blasts demonstrate the greatest alteration in the OPG/
RANKL system. Taken together, these alterations lead to
an altered bone remodelling rate in the T2DM, which
may, at least partially, explain the reduced bone strength
and increased incidence of non-traumatic fractures in
these patients.
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